Table 1.
Cohort demographics.
| Variables | Hemodialysis (n = 48) | Kidney Transplant (n = 52) |
|---|---|---|
| Age (mean years ± SD) | 68.3 ± 13.9 | 53.7 ± 12.7 |
| Gender | ||
| Female | 12 (25.0%) | 17 (32.7%) |
| Male | 36 (75.0%) | 35 (67.3%) |
| BMI (mean kg/m2 ± SD) | 26.2 ± 3.5 | 26.8 ± 4.6 |
| Primary vaccination schedule | ||
| CoronaVac | 42 (87.5%) | 35 (67.3%) |
| BNT162b2 | 6 (12.5%) | 17 (32.7%) |
| CKD etiology | ||
| Mellitus diabetes | 15 (31.2%) | 7 (13.5%) |
| Unknown | 20 (41.7%) | 13 (25.0%) |
| Glomerular | 8 (16.7%) | 18 (34.6%) |
| Congenital/genetic | 4 (8.3%) | 11 (21.1%) |
| Others | 1 (2.1%) | 3 (5.8%) |
| Time after kidney replacement therapies:Hemodialysis or transplant (mean days ± SD) | 1915 ± 1786 | 2125.6 ± 6007.3 |
| Immunosuppression | None of the patients received pharmacological immunosuppression. | |
| FK+MPA+PND | 36 (69.2%) | |
| FK+Aza+PND | 4 (7.7%) | |
| FK+Eve+PND | 7 (13.5%) | |
| FK+Rapa+PND | 1 (1.9%) | |
| CSA+Aza+PND | 2 (3.8%) | |
| Belatacept | 2 (3.8%) | |
| Charlson Score (mean ± SD) | 6 ± 2.7 | 4 ± 2.1 |
| Death | 2 (4.2%) | 1 (1.9%) |
SD = standard deviation; BMI = body mass index; CKD = chronic kidney disease; FK = tacrolimus; MPA = mycophenolic acid or sodium mycophenolate; PND = prednisone; Aza = azathioprine, Eve = everolimus, Rapa = rapamycin; CSA = cyclosporine.